Innovative Cellular Therapeutics Announces Data at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
ICT’s lead “armored” CAR-T program, ICTCAR014, demonstrated responses in two patients treated for refractory diffuse large B-cell lymphoma (DLBCL) in an investigator-sponsored clinical trial in China; safe and well-tolerated Currently in preclinical development in the U.S. for the treatment of Non-Hodgkin Lymphoma ROCKVILLE, Md., May 08, 2019 (GLOBE NEWSWIRE) — Innovative Cellular Therapeutics (ICT), a biotechnology…